HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ryuzo Kawamori Selected Research

1,2- diarachidonoyl- glycero- 3- phosphocholine

6/2010The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
8/2006Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ryuzo Kawamori Research Topics

Disease

93Type 2 Diabetes Mellitus (MODY)
09/2021 - 01/2002
46Insulin Resistance
12/2021 - 05/2003
20Atherosclerosis
01/2014 - 08/2003
18Hyperglycemia
03/2015 - 11/2002
18Hypertension (High Blood Pressure)
01/2014 - 07/2003
16Cardiovascular Diseases (Cardiovascular Disease)
02/2016 - 10/2005
11Glucose Intolerance
05/2021 - 07/2003
11Hypoglycemia (Reactive Hypoglycemia)
08/2017 - 08/2004
9Body Weight (Weight, Body)
09/2021 - 12/2005
9Diabetes Mellitus
02/2014 - 06/2005
8Diabetic Nephropathies (Diabetic Nephropathy)
08/2010 - 01/2002
7Stroke (Strokes)
01/2015 - 04/2009
7Carotid Artery Diseases
01/2014 - 08/2003
5Abdominal Obesity
01/2022 - 06/2006
5Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2021 - 08/2007
5Hypercholesterolemia
05/2013 - 06/2007
4Hyperinsulinism (Hyperinsulinemia)
10/2019 - 06/2006
4Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2019 - 12/2004
4Inflammation (Inflammations)
08/2017 - 10/2006
4Diabetes Complications
09/2013 - 07/2006
3Obesity
09/2021 - 06/2006
3Dyslipidemias (Dyslipidemia)
01/2015 - 01/2014
3Albuminuria
03/2013 - 03/2003
3Diabetic Retinopathy (Retinopathy, Diabetic)
07/2010 - 05/2005
3Proteinuria
02/2010 - 12/2002
3Coronary Disease (Coronary Heart Disease)
02/2010 - 12/2004
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2017 - 04/2010
2Neuralgia (Stump Neuralgia)
01/2016 - 04/2011
2Fatty Liver
03/2015 - 06/2006
2Ischemic Stroke
01/2015 - 04/2009
2Prediabetic State (Prediabetes)
01/2015 - 10/2008
2Vascular System Injuries
06/2014 - 02/2011
2Cerebral Infarction
01/2014 - 05/2009

Drug/Important Bio-Agent (IBA)

54Insulin (Novolin)FDA Link
09/2021 - 05/2003
48Glucose (Dextrose)FDA LinkGeneric
05/2021 - 07/2003
22LipidsIBA
12/2020 - 08/2003
14Blood Glucose (Blood Sugar)IBA
05/2021 - 07/2003
10Pharmaceutical PreparationsIBA
08/2017 - 01/2005
9Antihypertensive Agents (Antihypertensives)IBA
02/2016 - 10/2006
9Pioglitazone (Actos)FDA Link
01/2015 - 05/2007
9Hypoglycemic Agents (Hypoglycemics)IBA
06/2014 - 11/2002
8Triglycerides (Triacylglycerol)IBA
01/2019 - 06/2006
8Nonesterified Fatty Acids (NEFA)IBA
08/2017 - 06/2005
7Metformin (Glucophage)FDA LinkGeneric
08/2017 - 06/2004
7insulin aspart protamine drug combination 30:70 insulin aspartIBA
06/2013 - 01/2005
7Insulin Glargine (Lantus)FDA Link
08/2008 - 01/2005
6Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2014 - 04/2005
6Rosuvastatin Calcium (Crestor)FDA Link
01/2014 - 01/2009
6Glycoside Hydrolase InhibitorsIBA
11/2013 - 06/2004
6Nateglinide (Starlix)FDA LinkGeneric
06/2012 - 11/2002
6voglibose (Basen)IBA
01/2011 - 11/2002
6CreatinineIBA
11/2010 - 01/2002
5Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
09/2021 - 01/2005
5AlbuminsIBA
01/2017 - 04/2009
5olmesartanIBA
02/2016 - 01/2008
5Dipeptidyl-Peptidase IV InhibitorsIBA
01/2016 - 03/2010
4LDL CholesterolIBA
01/2015 - 01/2009
4oxidized low density lipoproteinIBA
01/2013 - 12/2004
4Pravastatin (Pravachol)FDA LinkGeneric
01/2013 - 06/2007
4Angiotensin Receptor AntagonistsIBA
01/2012 - 10/2004
4candesartanIBA
02/2011 - 06/2006
4Calcium Channel Blockers (Blockers, Calcium Channel)IBA
09/2009 - 10/2006
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2022 - 01/2009
3ORALIT (ORS)IBA
12/2021 - 12/2004
3AdiponectinIBA
01/2021 - 02/2012
3Biomarkers (Surrogate Marker)IBA
07/2020 - 06/2010
3HDL CholesterolIBA
01/2019 - 12/2009
3repaglinide (Prandin)FDA Link
03/2016 - 06/2012
3Hemoglobins (Hemoglobin)IBA
01/2015 - 05/2005
3Atorvastatin (Lipitor)FDA Link
05/2013 - 06/2005
3azelnidipineIBA
03/2013 - 12/2007
3Amlodipine (Norvasc)FDA LinkGeneric
01/2012 - 10/2006
3PotassiumIBA
08/2011 - 09/2008
3Cilostazol (Pletal)FDA LinkGeneric
06/2010 - 12/2004
3glimepiride (Amarel)FDA LinkGeneric
02/2010 - 01/2008
3CholesterolIBA
09/2009 - 08/2003
3ElementsIBA
09/2009 - 06/2006
3biphasic human insulin 30IBA
08/2009 - 01/2005
3InsulinsIBA
08/2009 - 01/2005
3epalrestatIBA
01/2009 - 07/2006
3Telmisartan (Micardis)FDA Link
04/2008 - 06/2007
3Short-Acting InsulinIBA
12/2007 - 01/2005
3Isophane Insulin (NPH Insulin)FDA Link
12/2007 - 01/2005
3Angiotensin II Type 1 Receptor BlockersIBA
04/2007 - 06/2006
3Insulin Aspart (NovoLog)FDA Link
02/2007 - 01/2005
3Transcription Factors (Transcription Factor)IBA
11/2006 - 01/2005
26- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
09/2021 - 01/2021
2Sodium-Glucose Transporter 2 InhibitorsIBA
09/2021 - 01/2021
2Protons (Proton)IBA
12/2020 - 01/2013
2Sitagliptin Phosphate (Januvia)FDA Link
03/2016 - 03/2015
2Duloxetine Hydrochloride (Cymbalta)FDA Link
01/2016 - 04/2011
2Fatty Acids (Saturated Fatty Acids)IBA
09/2014 - 05/2008
2SodiumIBA
01/2014 - 08/2011
2Glucagon-Like Peptide 1 (GLP 1)IBA
11/2013 - 09/2008
2Olmesartan Medoxomil (Votum)FDA Link
12/2012 - 11/2008

Therapy/Procedure

33Therapeutics
03/2016 - 12/2004
25Glycemic Control
08/2017 - 08/2003
3Exercise Therapy (Therapy, Exercise)
08/2017 - 06/2005
2Surgical Amputation (Amputations)
01/2018 - 02/2010
2Secondary Prevention
01/2014 - 04/2010